The results showed that BLCA patients in low-risk group were more likely to response to PD-1 blockade (Bonferroni corrected P = 0.014), and high-risk groups were more likely to response to CTLA-4 blockade (Bonferroni corrected P = 0.041) (Fig. 7A). The gene discussed is CTLA4; the disease is bladder transitional cell carcinoma.